文献速递腹部CTMR

索拉非尼治疗肝细胞癌的肿瘤反应评估:操作者间变异性与误差来源

Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
PubMed 文献 · Eur Radiol · 2018-04-09

本回顾性研究纳入2008年9月至2015年2月接受索拉非尼治疗的肝细胞癌患者,由三名肝脏影像专业水平不同的放射科医生分别按RECIST 1.1、mRECIST和RECICL标准评估影像。结果显示,两名高年资操作者间总体反应一致性良好(RECIST 1.1 κ=0.840,mRECIST κ=0.871,RECICL κ=0.819),而低年资操作者与同事间一致性较低;靶病灶反应评估中,专家操作者分歧主要源于病灶选择,低年资操作者主要源于病灶测量。结论认为,索拉非尼治疗下患者反应或进展的判断可能因操作者而异,尤其对未接受专门培训的放射科医生;无论采用何种标准,应由经验丰富的放射科医生评估以尽量减少变异性。

要点

  • 高年资操作者间总体反应一致性良好,不同标准κ值在0.819至0.871之间。
  • 专家操作者间靶病灶评估分歧主要源于病灶选择。
  • 未接受专门肝脏影像培训的操作者与同事间一致性较低,主要分歧源于病灶测量。

核心结论

  • 索拉非尼治疗下患者是反应者还是进展者的判断可能因操作者而异,尤其对未接受专门培训的放射科医生;无论采用何种标准,应由经验丰富的放射科医生评估以尽量减少变异性。

研究设计与样本

  • 回顾性研究,纳入2008年9月至2015年2月接受索拉非尼治疗的所有肝细胞癌患者,由三名肝脏影像专业水平不同的放射科医生(操作者1:>10年经验;操作者2:5年经验;操作者3:无肝脏影像专门培训)分别按RECIST 1.1、mRECIST和RECICL标准独立评估影像。

诊断标准与关键数值

  • 高年资操作者间总体反应一致性:RECIST 1.1 κ=0.840,mRECIST κ=0.871,RECICL κ=0.819。

临床应用与阅片要点

  • 作者认为,无论采用何种反应标准,应由经验丰富的放射科医生评估索拉非尼治疗患者的肿瘤反应,以尽量减少变异性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the inter-operator concordance and the potential sources of discordance in defining response to sorafenib in hepatocellular carcinoma (HCC).

METHODS: All patients who received sorafenib between September 2008 and February 2015 were scrutinised for this retrospective study. Images were evaluated separately by three radiologists with different expertise in liver imaging (operator 1, >10 years; operator 2, 5 years; operator 3, no specific training in liver imaging), according to: response evaluation radiological criteria in solid tumours (RECIST) 1.1, modified RECIST (mRECIST) and response evaluation criteria in cancer of the liver (RECICL).

RESULTS: The overall response concordance between the more expert operators was good, irrespective of the criteria (RECIST 1.1, ĸ = 0.840; mRECIST, ĸ = 0.871; RECICL, ĸ = 0.819). Concordance between the less expert operator and the other colleagues was lower. The most evident discordance was in target lesion response assessment, with expert operators disagreeing mostly on lesion selection and less expert operators on lesion measurement. As a clinical correlate, overall survival was more tightly related with "progressive disease" as assessed by the expert compared to the same assessment performed by operator 3.

CONCLUSIONS: Decision on whether a patient is a responder or progressor under sorafenib may vary among different operators, especially in case of a non-specifically trained radiologist. Regardless of the adopted criteria, patients should be evaluated by experienced radiologists to minimise variability in this critical instance.

KEY POINTS: • Inter-operator variability in the assessment of response to sorafenib is poorly known. • The concordance between operators with expertise in liver imaging was good. • Target lesions selection was the main source of discordance between expert operators. • Concordance with non-specifically trained operator was lower, independently from the response criteria. • The non-specifically trained operator was mainly discordant in measurements of target lesions.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Tovoli F, Renzulli M, Negrini G, et al. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radiol. 2018. PMID: 29633000. doi:10.1007/s00330-018-5393-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。